Key Details
Price
$3.83Last Dividend
$5.25Annual ROE
-70.72%Beta
1.30Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 13, 2012Next split:
N/ARecent split:
May 10, 2017Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESSWIRE / November 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.
Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer's drug, simufilam.
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
NEW YORK CITY, NY / ACCESSWIRE / November 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Cassava Sciences SAVA stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study
FAQ
- What is the primary business of Cassava Sciences?
- What is the ticker symbol for Cassava Sciences?
- Does Cassava Sciences pay dividends?
- What sector is Cassava Sciences in?
- What industry is Cassava Sciences in?
- What country is Cassava Sciences based in?
- When did Cassava Sciences go public?
- Is Cassava Sciences in the S&P 500?
- Is Cassava Sciences in the NASDAQ 100?
- Is Cassava Sciences in the Dow Jones?
- When was Cassava Sciences's last earnings report?
- When does Cassava Sciences report earnings?
- Should I buy Cassava Sciences stock now?